Rate this post

Ginkgo Bioworks is a notable American biotechnology company established in 2008. The company was founded by a group of five scientists hailing from the Massachusetts Institute of Technology (MIT), with Jason Kelly leading the team. For more detailed information, you can refer to the company’s Wikipedia page.

Ginkgo Bioworks – Company Highlights

Stock PriceDNA (NYSE) $1.79 +0.13 (+7.83%)
Stock last updated:Aug 23, 4:00 PM EDT
Revenue478 million USD (2022)
HeadquartersBoston, MA
FounderReshma P. Shetty
SubsidiariesGinkgo Bioworks Inc., Zymergen
PresidentReshma P. Shetty
CEOJason Kelly

Ginkgo Bioworks – About

Ginkgo Bioworks, also known as “The Organism Company,” is a leading player in the field of synthetic biology. Their ambitious goal is to establish the first platform company in this domain, a goal that has generated both enthusiastic support and critical skepticism. This essay intends to explore some of the major concepts that Ginkgo Bioworks is pursuing, offering insight into the potential trajectory of synthetic biology as a whole.

Currently, Ginkgo Bioworks is utilizing their platform to engineer microorganisms with a range of applications. These applications include creating sustainable agriculture solutions, producing valuable chemicals through microbial engineering, and enabling targeted delivery of therapeutics.

Ginkgo Bioworks – Industry

The biotechnology industry, within which Ginkgo Bioworks operates, is a multifaceted field with significant growth potential. As of 2023, the industry has been experiencing steady expansion, driven by advancements in healthcare, agriculture, industrial processes, and other sectors. The integration of biotechnology with other technologies, along with its global reach, indicates promising growth opportunities through 2025 and beyond.

The biotechnology industry is characterized by intense competition among both established companies and startups.

As of the latest available data, the biotechnology industry has shown impressive growth. The market size and revenue of biotech companies continue to expand globally by USD 1,094.6 Billion in 2022 and is projected to reach a value of USD 2772.7 Billion by 2030 at a CAGR (Compound Annual Growth Rate) of 14.2% between 2023 and 2030.

Ginkgo Bioworks operates within the biotechnology industry, a dynamic sector that harnesses biological systems, organisms, and cellular processes to develop innovative products and solutions across various domains.

Ginkgo Bioworks – Founders

Jason KellyFOUNDER
Reshma ShettyFOUNDER
Barry CantonFOUNDER
Source: Official website

Jason Kelly

Jason Kelly is a prominent figure in the field of biotechnology and a co-founder of Ginkgo Bioworks. With a visionary outlook, Kelly has been a driving force behind the company’s groundbreaking advancements. As the CEO, he has led Ginkgo Bioworks in its mission to leverage synthetic biology for diverse applications.

Reshma Shetty

Reshma Shetty is a co-founder of Ginkgo Bioworks and a significant figure in the biotechnology landscape. As one of the original founders, Shetty has played a pivotal role in shaping the company’s vision and direction. Her contributions have been instrumental in Ginkgo’s rise as a leading force in synthetic biology.

Shetty’s scientific expertise and entrepreneurial spirit have been key drivers behind Ginkgo’s success. With a background in biological engineering, she has been instrumental in bridging the gap between cutting-edge science and practical applications.

Barry Canton

Barry Canton is a co-founder of Ginkgo Bioworks and a key influencer in the biotechnology realm. As one of the original founders, Canton has played a pivotal role in shaping the company’s trajectory and accomplishments.

Canton’s expertise in synthetic biology and his innovative mindset have been fundamental to Ginkgo’s success. With a background in biological engineering, he has been instrumental in translating complex scientific concepts into tangible applications.

Austin Che

Austin Che is a co-founder of Ginkgo Bioworks, making significant contributions to the company’s growth and accomplishments. As one of the original founders, Che has been instrumental in shaping Ginkgo’s journey as a pioneering force in the field of synthetic biology.

By co-founding Ginkgo, Che has also become an advocate for the transformative power of biotechnology. His dedication to creating solutions that address challenges in industries ranging from healthcare to manufacturing has positioned Ginkgo as a trailblazer in the biotech sector.

Tom Knight

Tom Knight is a co-founder of Ginkgo Bioworks and a central figure in the company’s impactful journey in the field of synthetic biology. As one of the original founders, Knight’s contributions have been pivotal in shaping Ginkgo’s vision and accomplishments.

Tom Knight’s role as a co-founder of Ginkgo Bioworks underscores his innovative thinking, interdisciplinary expertise, and dedication to advancing the field of synthetic biology.

Knight’s involvement highlights his dedication to the advancement of synthetic biology as a transformative technology. His work with Ginkgo exemplifies his commitment to pushing the boundaries of what’s possible at the intersection of biology and technology.

Key Financial Highlights from Ginkgo Bioworks’ Q2 2023

This financial report is officially shared by Ginkgo Bioworks in a press release published on PR News Wire.

MetricQ2 2023
Total revenue$81 million
Cell Engineering revenue$45 million
Cell Engineering services revenue growth+72% year-over-year
Biosecurity revenue$35 million
Biosecurity gross margin49%
New Cell Programs added21
Loss from operations$184 million
Adjusted EBITDA-$75 million
Cash and cash equivalents$1.1 billion
Full year 2023 guidance:
– Total revenue$245-$260 million
– Cell Engineering revenue$145-$160 million
– Biosecurity revenueAt least $100 million
– New Cell Programs100

The key highlights are the 72% growth in Cell Engineering services revenue, the addition of 21 new Cell Programs, and the maintenance of a strong cash position of $1.1 billion. The outlook projects continued Cell Engineering growth and at least 100 new Cell Programs for 2023.

Ginkgo Bioworks Investors

General AtlanticExited
Bill GatesExited
Cascade InvestmentExited
Viking Global InvestorsExited
Y Combinator (Formerly Cambridge Seed)Exited
Farzad (Zod) NazemExited
iGlobe PartnersExited
Vast VenturesExited
OS FundExited
David BeyerExited
Felicis VenturesExited
Senator Investment GroupExited
Baillie GiffordExited
Allen & CompanyExited
11.2 CapitalExited
Ian McNishExited
Catapult VCExited
Azure Capital PartnersExited
Soaring Eagle Acquisition CorpExited
Putnam InvestmentsExited
Morgan StanleyExited
Bain CapitalExited
T. Rowe Price (Formerly Rowe Price-Fleming International)Exited
Next Ventures UKExited
ARK InvestActive
Hemisphere VenturesExited
NSF – National Science FoundationExited
Small Business Innovation Research (SBIR)Exited
Starling VenturesExited
Starling VenturesExited
N/AFarzad (Zod) Nazemi, Globe Partners, Vast Ventures, OS Fund, David Beyer, Felicis Ventures, Senator Investment Group, Allen & Company, 11.2 Capital, Ian McNish, Catapult VC, Azure Capital Partners, Next Ventures UK, MassVentures, TSVC, In-Q-Tel, and more
Dec 2017*General Atlantic, Y Combinator (Formerly Cambridge Seed), Bill Gates, Cascade Investment, Viking Global Investors$275mSeries D
Sep 2019General Atlantic, Cascade Investment, Viking Global Investors$290mSeries E
May 2020*General Atlantic, Illumina, Viking Global Investors$70.0mLate VC
May 2021Bain Capital, Morgan Stanley, Baillie Gifford, Putnam Investments, Cascade Investment, ARK Invest, T. Rowe Price (Formerly Rowe Price-Fleming International)$775mSPAC Private Placement
May 2021Soaring Eagle Acquisition Corp$1.7bSPAC IPO
Oct 2021ARK Invest$15.9mPost IPO Equity
Total Funding$1.6b

The information provided in the table is verified from reliable sources as it pertains to financial and investment data. Our main source of data is CrunchBase.

With a funding journey that mirrors its pioneering spirit. Since its inception, the company has secured a total funding of $1.6 billion, a testament to its transformative potential.

Early backers, including Farzad (Zod) Nazemi and venture firms like Globe Partners and Vast Ventures, recognized Ginkgo’s promise. The momentum escalated with notable figures like Bill Gates joining the fold, and strategic partnerships with Illumina and Viking Global Investors.

Key milestones dot the funding trajectory. A robust Series D round in 2017, including General Atlantic and Y Combinator, set the stage. A subsequent Series E round in 2019 raised $290 million, elevating Ginkgo’s valuation to $3.9 billion.

Mergers & Acquisition of Ginkgo Bioworks

Transaction NameAcquiree NameAcquirer NameAnnounced Date
Altar acquired by Ginkgo BioworksAltarGinkgo BioworksOct 4, 2022
Circularis Biotechnologies acquired by Ginkgo BioworksCircularis BiotechnologiesGinkgo BioworksOct 4, 2022
Zymergen acquired by Ginkgo BioworksZymergenGinkgo BioworksJul 25, 2022
Bitome acquired by Ginkgo BioworksBitomeGinkgo BioworksJun 6, 2022
Dutch DNA acquired by Ginkgo BioworksDutch DNAGinkgo BioworksMay 17, 2021

Here is a more detailed summary of Ginkgo Bioworks’ key M&A transactions:

Altar – Ginkgo acquired Altar in October 2022 for $150 million in cash and stock. Altar is a clinical-stage biotech company focused on developing engineered immune cells for cancer therapies. The acquisition expands Ginkgo’s capabilities in cell therapy and gene engineering.

Circularis Biotechnologies – Ginkgo acquired Circularis in October 2022 for $44 million in cash. Circularis is a metabolic engineering company that designs microbes to produce sustainable chemicals. The acquisition strengthens Ginkgo’s cell programming abilities for specialty chemicals.

Zymergen – Ginkgo’s largest acquisition to date is Zymergen in July 2022 for $300 million in cash and stock. Zymergen is a synthetic biology company with proprietary AI and automation technologies. The acquisition provided Ginkgo with additional infrastructure, talent, and IP in organism engineering.

Bitome – Ginkgo acquired Bitome, a DNA synthesis company, in June 2022 for $44 million in cash and stock. The acquisition allows Ginkgo to expand and control a key part of its organism engineering workflow.

Dutch DNA – Ginkgo acquired Dutch DNA in May 2021 for $44 million in cash and stock. Dutch DNA is a DNA synthesis provider focused on the European market. The acquisition expanded Ginkgo’s global footprint and DNA synthesis capabilities.

In summary, Ginkgo has made strategic acquisitions to expand its cell programming platform, add new capabilities in cell and gene therapies, boost its DNA synthesis and data/AI assets, and grow its global presence. The deals have been funded through a mix of cash and stock and ranged in size from $44 million to $300 million.

To check full list of M&A of Ginkgo Bioworks – you can check this page on crunchbase.

Ginkgo Bioworks – Business Model and Revenue Model

Business Model:

  • Ginkgo operates an organism engineering foundry that allows customers to rapidly prototype and develop organisms engineered for a wide range of end products.
  • It provides an end-to-end platform for designing, building, testing and scaling production of engineered organisms.
  • The foundry business model is designed to democratize access to synthetic biology R&D by providing services and infrastructure.

Revenue Model:

  • Cell Programming Services – Ginkgo charges partners R&D fees for using its foundry platform and engineering services to develop new organisms. This makes up the majority of its cell engineering revenue.
  • Milestone Payments – Ginkgo structures some partnerships to receive milestone payments as programs advance through stages of development.
  • Royalties – For certain commercialized products developed using its foundry, Ginkgo receives royalty payments on product sales.
  • Product Sales – For some organism programs Ginkgo develops, it pursues commercialization itself and generates revenue from end product sales.
  • Biosecurity – Ginkgo’s Concentric subsidiary provides various biosecurity services like pathogen monitoring, test development, etc. to public health agencies.

Key Takeaways:

  • Platform-as-a-service business model focused on synthetic biology R&D
  • Multiple revenue streams from R&D services, milestones, royalties, product sales, and biosecurity
  • Business model designed to scale program volume and drive recurring revenue

Ginkgo – Competitors

CompetitorFunding Status
Algal BioPrivately-held
Biosortia MicrobiomicsPrivately-held
RedLeaf BiologicsPrivately-held
HiChina Web SolutionsPrivately-held

I added a column indicating whether each competitor is privately-held or publicly-traded. This provides useful context on their funding situation and stage of development.

Ginkgo Bioworks – Future Plans

Ginkgo Bioworks is embarking on an ambitious venture, leveraging its strain design technology in collaboration with Sumitomo Chemical. The joint effort aims to create a microbial strain and refine the fermentation process for efficient production of the targeted molecule. Simultaneously, Sumitomo Chemical will lead the development of the manufacturing process and its scaling for eventual commercialization.

Analyst Price Forecasts:

Market analysts have weighed in on Ginkgo Bioworks Holdings Inc’s future. Twelve-month price predictions reveal a median target of $3.00, accompanied by a high estimate of $12.00 and a low projection of $1.25. This median forecast implies a substantial 86.34% increase from the latest recorded price of $1.61.

DNA Stock Price Prediction for 2030:

Looking ahead to 2030, DNA Stock’s price prediction comes into focus. An analysis suggests optimistic prospects, anticipating an average price of $24 and a potential maximum price of $30, provided favorable conditions prevail.

Future Growth Assessment:

Considering Ginkgo Bioworks Holdings’ future trajectory, key criteria are under scrutiny. Earnings and revenue are expected to witness robust growth rates of 76% and 24.7% per annum, respectively. The projection for EPS growth stands at an impressive 77.3%. However, the anticipated return on equity over the span of three years is estimated at -62.6%, raising certain considerations for the company’s financial performance.


Who are Ginkgo Bioworks Competitors?

Here are the names of the top 5 competitors of Ginkgo Bioworks in the field of synthetic biology and biotechnology:

Twist Bioscience
Intrexon (now Precigen)

Who are ginkgo bioworks customers?

Ginkgo Bioworks’ customers span industries such as agriculture, healthcare, chemicals, consumer goods, and environmental solutions, seeking innovative synthetic biology solutions for improved crop yield, drug discovery, sustainable materials, and more.

Who owns ginkgo bioworks?

Ginkgo Bioworks is a privately held company, and its ownership is distributed among its founders, investors, and stakeholders. Reshma Shetty is president of Ginkgo bioworks.

Is Ginkgo Bioworks profitable?

No, Ginkgo Bioworks is not yet profitable. The company reported a net loss of $669 million in 2021 and a net loss of $1.1 billion for the first 9 months of 2022. Ginkgo has focused on platform expansion over profitability so far.

When Ginkgo Bioworks go public?

Ginkgo Bioworks went public through a merger with Soaring Eagle Acquisition Corp. (SPAC) on September 16, 2021. Its shares started trading on the NYSE under the ticker symbol “DNA” on September 17, 2021

0 CommentsClose Comments

Leave a Reply